A Generalized Risk Adjusted Cost Effectiveness (GRACE) Economic Model for Measuring the Value of Interventions that Delay Mobility Impairment Across Neurological Conditions
That is the title of a new paper out in Value in Health with co-authors Jaehong Kim, Jacob Fajnor, Kyi-Sin Than, Elizabeth S. Mearns , Stacey L. Kowal, Thomas Majda and Jakub P. Hlávka PhD. The abstract is below. Objectives To quantify how incorporating patient risk preferences and severity adjustments affect the value of a…